- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Gina Libby strives to improve pain medication legislation
- Chronic pain sufferer Dennis Kinch pens book to encourage pain community
- New York's online database of drug prescriptions curtailing 'doctor shopping'
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
MENLO PARK, Calif. — Depomed has launched a new drug for treating shingles, the drug maker said Monday.
The company announced the launch of Gralise (gabapentin) tablets, a once-daily treatment for postherpetic neuralgia, the pain that follows healing of the rash associated with shingles.
Gralise is a proprietary formulation of gabapentin that uses patented polymer technology that enables gradual release of the drug. Depomed said it is not interchangeable with other branded or generic gabapentin-based drugs.